An observational study in Migraine, sponsored by University Hospital, Clermont-Ferrand. Recruiting at 1 site in France. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-03-09.
Sponsored by University Hospital, Clermont-Ferrand · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Migraine Disorders with a site in France — 14 open to participants now, 20 under way, 6 of them phase 3. Migraine Disorders · France.
Among the 71 studies in Migraine Disorders with a site in France, this one is the 11th largest by planned enrollment of the 20 observational ones that give a count, is one of 5 that started in 2026, is one of 20 observational ones, reaches primary completion later than 13 of the 19 other live ones, and was the 68th registered.
1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →14 of the 71 studies in Migraine Disorders with a site in France are open now. Recruiting first, the newest first:
University Hospital, Clermont-Ferrand · Sites in France
Ages 18–50 · Women only · Healthy volunteers
University Hospital, Clermont-Ferrand · Sites in France
Ages 18–50 · Women only · Healthy volunteers
Hôpital Européen Marseille · Sites in France
Ages 18–60
University Hospital, Clermont-Ferrand · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 144 is close to the median of 138 across 332 observational studies indexed under Migraine Disorders.
Median enrollment 450 across the 51 interventional studies, 155 across the 20 observational. Of the 45 that completed or were terminated, 19 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 71 have an industry lead sponsor. The 10 most frequent:
University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 177 are open to participants now.
University Hospital, Clermont-Ferrand has 9 studies filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
7 of the studies in Migraine Disorders with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07018700Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine | 2027-03 |
| NCT07018713Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine | 2027-03 |
| NCT06426316University Hospital, Clermont-FerrandThe Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology. | 2027-04-30 |
| NCT07598045University Hospital, Clermont-FerrandEfficacy of Anti-IL-6 Treatments on Migraine in Patients Treated With Anti-IL-6 for a Rheumatological Condition | 2027-05-26 |
| NCT06625060IpsenA Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults | 2027-10-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 71 studies in Migraine Disorders with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Migraine is a leading cause of disability, and while triptans are commonly used to treat migraine attacks, over 20% of patients don't respond well to them. This study aims to understand why some people don't benefit from triptans. One key focus is tryptophan, an amino acid that plays a role in migraine and is involved in producing serotonin, which affects pain and inflammation. The study will compare levels of tryptophan and its by-products in patients who respond well to triptans versus those who don't. It will also look at how conditions like inflammatory bowel disease may affect tryptophan absorption. The goal is to improve migraine treatments tailored to different patient needs, though participants may not experience immediate personal benefits.
Migraine is a leading cause of disability worldwide. Triptans are medications used to treat migraine attacks. They work mainly in two ways: by narrowing the blood vessels in the brain and by stopping the release of substances that cause pain and inflammation. Triptans help relieve migraine pain and other symptoms, like digestive problems, light sensitivity, and disability during an attack. However, more than 20% of patients do not respond well to these medications, and the reasons for this are not well understood.
Tryptophan is an essential amino acid, which means it must come from food because the body cannot produce it. Tryptophan plays an important role in migraines, especially through its by-products, such as serotonin and kynurenine. Research has shown that problems with tryptophan metabolism can make migraines worse, along with other sensory symptoms.
Although no study has directly linked tryptophan to the effectiveness of triptans, the investigators found in a preclinical study that a low-tryptophan diet could reduce the effectiveness of sumatriptan, one of the most commonly used triptans. A deficiency in tryptophan can occur when the body has trouble absorbing it from the intestines. Conditions like inflammatory bowel diseases (such as irritable bowel syndrome or Crohn's disease) or diabetes can affect this absorption, which might reduce the body's ability to process tryptophan.
This study aims to better understand how tryptophan might affect resistance to triptans in migraine patients. The investigators will compare blood levels of tryptophan and its by-products in patients who respond well to triptans versus those who do not. If participants are having a lumbar puncture as part of their regular check-up, the investigators will also examine these substances in the cerebrospinal fluid. Additionally, the investigators will explore any connection between tryptophan metabolism and inflammatory bowel disease.
Participants in the study will be recruited from the following centers:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Blood collection
Biological: Blood collection
Blood collection
Biological: Blood collection
Blood sampling. For patients who have had their cerebrospinal fluid sample taken as part of their treatment, a surplus sample will be used to perform the same measurements.
Plasma tryptophan levels
Variation in plasma tryptophan levels between triptan-resistant and triptan-responsive migraine patients.
Time frame: Baseline
Serotonin levels
Variation in plasma serotonin levels between triptan-resistant and triptan-responsive migraine patients.
Time frame: Baseline
Kynurenine levels
Variation in plasma kynurenine levels between triptan-resistant and triptan-responsive migraine patients.
Time frame: Baseline
Levels of neutral amino acids
Variation in plasma levels of neutral amino acids between triptan-resistant and triptan-responsive migraine patients.
Time frame: Baseline
Levels of cytokines (IL-6, IL-10, IL-1α, IL-1β)
Variation in plasma levels of cytokines (IL-6, IL-10, IL-1α, IL-1β) between triptan-resistant and triptan-responsive migraine patients.
Time frame: Baseline
Dietary tryptophan intake
Dietary tryptophan intake via a self-questionnaire on eating habits
Time frame: Baseline
Inflammatory bowel disorders
Presence/absence of inflammatory bowel disorders
Time frame: Baseline
Blood nutritional biomarkers
Variation in blood nutritional biomarkers (glycemia, cholesterol)
Time frame: Baseline
Hospital Anxiety and Depression Scale
Tool for assessing levels of anxiety and depression in patients
Time frame: Baseline
Headache Impact
The HIT-6 will be used to assess the impact of headaches on a person's daily life
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Mar 2028, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Clermont-Ferrand →